COVID-19 in hematopoietic cell transplant recipients

Altuntaş, Fevzi; Ata, Naim; Yiğenoğlu, Tuğçe Nur; Başçı, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Namdaroğlu, Sinem; Baştürk, Abdulkadir; Hacıbekiroğlu, Tuba; Doğu, Mehmet Hilmi; Berber, İlhami; Dal, Kürşat; Erkurt, Mehmet Ali; Turgut, Burhan; Ülgü, Mustafa Mahir; Çelik, Osman; Akunal, Abdullah; Birinci, Şuayıp

doi:10.1038/s41409-020-01084-x

Cited by 26 publications

(56 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 Kanellopoulus et al reported a mortality rate of 43%. 20 Altunas et al reported a fatality rate of 16% 21 whereas Sultan et al reported survival of 100% in a small cohort (n = 7) that included some patients with severe disease. 22 Perhaps the most reliable data regarding 30-day mortality in HCT patients with COVID-19, due to large sample size (>300 patients) and multicenter design, are the recent publication by CIBMTR with reported 30-day mortality of 32% and 33% for allogeneic and autologous HCT recipients, respectively.…”

Section: Ta B L E 2 (Continued)mentioning

confidence: 99%

Clinical presentation and outcomes of COVID‐19 following hematopoietic cell transplantation and cellular therapy

Camargo

Mendoza

Lin

et al. 2021

Transplant Infectious Dis

View full text Add to dashboard Cite

Background: One year into the pandemic, published data on hematopoietic cell transplantation (HCT) recipients with coronavirus disease 2019 (COVID-19) remain limited. Methods: Single-center retrospective cohort study of adult HCT recipients with polymerase chain reaction (PCR)-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Results: Twenty-eight consecutive transplantation and cellular therapy patients (autologous, n = 12; allogeneic, n = 15; chimeric antigen receptor T-cell therapy [CAR-T], n = 1) with COVID-19 were identified. The median age was 57 years. The median time from HCT to COVID-19 diagnosis was 656 days (interquartile range [IQR], 33-1274). Patients were followed for a median of 59 days (IQR, 40-88).Among assessable patients (n = 19), 10 (53%) had documented virological clearance; median time to clearance was 34 days (range, 21-56). Out of 28, 12 (43%), 6 (21%), and 10 (36%) patients had mild, moderate, and severe/critical disease, respectively.Overall mortality was 25%, nearly identical for autologous and allogeneic HCT, and exclusively seen in hospitalized patients, older than 50 years of age with severe COVID-19. None of the patients with mild (n = 12) or moderate (n = 6) COVID-19 died whereas 7/10 patients (70%) with severe/critical COVID-19 died (P = .0001). Patients diagnosed with COVID-19 within 12 months of HCT exhibited higher mortality (57% vs 14%; P = .04). All-cause 30-day mortality (n = 4) was 14%. A higher proportion of patients who died within 30 days of COVID-19 diagnosis (3/4) were receiving ≥2 immunosuppressants, compared with patients who survived beyond 30 days after COVID-19 diagnosis (2/24; 75% vs. 8%; P = .01). Conclusions:Mortality in COVID-19 HCT patients is higher than that of the agecomparable general population and largely dependent on age, disease severity, timing from HCT, and intensity of immunosuppression.

show abstract

Section: Ta B L E 2 (Continued)mentioning

confidence: 99%

Clinical presentation and outcomes of COVID‐19 following hematopoietic cell transplantation and cellular therapy

Camargo

Mendoza

Lin

et al. 2021

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…In another study, the CFR was 15.6% in HSCT recipients. The CFR of the HSCT recipients who were receiving immunosuppressive treatment was reported as 33% in that study [10]. The patients on immunosuppressive treatment can be considered at high risk for COVID-19 as well as other viral infections.…”

Section: Discussionmentioning

confidence: 83%

The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients

Karataş¹,

Malkan²,

Velet³

et al. 2021

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: The disease caused by SARS-CoV-2 was named as COVID-19.There is as yet insufficient information about the effects of HSCT on the clinical course of COVID-19. In the present study, we aimed to investigate the clinical course of COVID-19 in patients who had undergone HSCT. Materials and methods:We analyzed baseline characteristics, clinical course and findings of COVID-19, hospitalization and death rates, overall survival and case fatality rates of HSCT recipients diagnosed with COVID-19 retrospectively.Results: 57.6% of the patients underwent AHSCT, and 42.4% underwent allo-HSCT. 60.6%, 27.3%, and 12.1% of the patients had mild, moderate and severe COVID-19 or critical illness, respectively. 45.5% were hospitalized, and 12.1% required intensive care. 9.1% necessitated invasive mechanical ventilation. The total CFR was 9.1% in HSCT recipients, 22.2% in patients with active hematologic malignancy and 4.2% in patients without active hematologic malignancy. Conclusion:It can be concluded that mortality of HSCT recipients is lower in patients whose primary disease is in remission compared to ones that are not in remission.Further studies with larger group patients are needed in order to delineate the effects of COVID-19 on HSCT patients.

show abstract

“…The risk for severe and fatal courses of COVID-19 is particularly high after allogeneic hematopoietic stem cell transplantation (alloSCT) [1][2][3][4]. Cardiovascular and renal morbidity is increased post COVID-19 [5].…”

Section: To the Editormentioning

confidence: 99%

Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection

Christopeit

Reichard

Niederwieser

et al. 2021

Bone Marrow Transplant

View full text Add to dashboard Cite

COVID-19 in hematopoietic cell transplant recipients

Cited by 26 publications

References 10 publications

Clinical presentation and outcomes of COVID‐19 following hematopoietic cell transplantation and cellular therapy

Clinical presentation and outcomes of COVID‐19 following hematopoietic cell transplantation and cellular therapy

The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients

Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection

Contact Info

Product

Resources

About